Bioethics Backlash

Bioethicists debate how to remain impartial as a bioethics journal editor joins company that peddles unproven stem cell therapies.

Sabrina Richards
Feb 22, 2012

Mesenchymal stem cell.WIKIMEDIA COMMONS, GHANSON

Bioethicists are debating how, or even whether, one can remain impartial when working for industry as Glenn McGee, founder and editor of the American Journal of Bioethics, joins CellTex, a company that banks patients’ cells for untested stem cell therapies, reported Nature. McGee, who joined CellTex in December of last year and will step down from AJOB on March 1, says he hopes to bring ethical standards to CellTex’s stem cell trials.

CellTex licenses therapies from RNL Bio, a South Korea-based company that converts patients’ fat cells into patient-specific mesenchymal stem cells, which the company claims can be reinjected to treat conditions like spinal cord injury. To date, no clinical trials have been completed that back these claims.

Though criticism has been leveled at McGee for joining CellTex while remaining at AJOB, observers also wonder whether bioethicists can work in industry...

“I know firsthand how difficult it is to separate conflict of interest—to maintain the role of bioethicist,” Hyun told Nature. “I know you need to not be too chummy with enterprises trying to speed ahead in stem cells.”

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?